' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

EGLE ALEXANDER
Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikationen | Forscherprofil

171 Publikationen

2019

Beiträge in Fachzeitschriften

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber, D; Wacht, N; Leisch, M; Qi, Y; Maeding, N; Hufnagl, C; Jansko, B; Zaborsky, N; Villunger, A; Hartmann, TN; Greil, R; Egle, A;
Clin Cancer Res. 2019; 25(6):1901-1912
Originalarbeiten (Zeitschrift)
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle, A; Melchardt, T; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Voskova, D; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Weiss, L; Magnes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R;
Cancer Med. 2019; 8(4):-1405.
Originalarbeiten (Zeitschrift)
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Katja, S; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A;
Eur J Haematol. 2019; 102(5):437-441
Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.
Leisch, M; Egle, A; Greil, R;
Future Oncol. 2019; 15(2):109-120
Originalarbeiten (Zeitschrift)
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2019;
Korrekturen
Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
Zaborsky, N; Gassner, FJ; Höpner, JP; Schubert, M; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Egle, A;
Leukemia. 2019; 33(4):957-968
Originalarbeiten (Zeitschrift)

2018

Beiträge in Fachzeitschriften

Remission maintenance treatment options in chronic lymphocytic leukemia.
Egle, A; Pleyer, L; Melchardt, T; Hartmann, TN; Greil, R;
Cancer Treat Rev. 2018; 70:56-66
Übersichtsarbeiten
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(9):1745
Korrekturen
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(10): 1825-1839.
Originalarbeiten (Zeitschrift)
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Pulverer, W; Weinhaeusel, A; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Risch, A; Greil, R
THERANOSTICS. 2018; 8(8): 2278-2288.
Originalarbeiten (Zeitschrift)
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
Gutjahr, JC; Szenes, E; Tschech, L; Asslaber, D; Schlederer, M; Roos, S; Yu, X; Girbl, T; Sternberg, C; Egle, A; Aberger, F; Alon, R; Kenner, L; Greil, R; Orian-Rousseau, V; Hartmann, TN;
Blood. 2018; 131(12): 1337-1349.
Originalarbeiten (Zeitschrift)
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Huemer, F; Weiss, L; Faber, V; Neureiter, D; Egle, A; Geissler, K; Voskova, D; Zebisch, A; Burgstaller, S; Pichler, A; Stauder, R; Sperr, W; Lang, A; Pfeilstöcker, M; Machherndl-Spandl, S; Stampfl, M; Greil, R; Pleyer, L;
Wien Klin Wochenschr. 2018; 130(3-4): 115-125.
Originalarbeiten (Zeitschrift)
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.
Janovska, P; Verner, J; Kohoutek, J; Bryjova, L; Gregorova, M; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Ovesna, P; Blanarova, OV; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Egle, A; Pavlova, S; Poppova, L; Plevova, K; Pospisilova, S; Bryja, V
BLOOD. 2018; 131(11): 1206-1218.
Originalarbeiten (Zeitschrift)
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2018; 18(3):-479
Originalarbeiten (Zeitschrift)
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt, T; Magnes, T; Hufnagl, C; Thorner, AR; Ducar, M; Neureiter, D; Tränkenschuh, W; Klieser, E; Gaggl, A; Rösch, S; Rasp, G; Hartmann, TN; Pleyer, L; Rinnerthaler, G; Weiss, L; Greil, R; Egle, A;
Eur J Cancer. 2018; 93:69-78
Originalarbeiten (Zeitschrift)
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Schlick, K; Magnes, T; Ratzinger, L; Jaud, B; Weiss, L; Melchardt, T; Greil, R; Egle, A;
PLoS One. 2018; 13(11): e0206688
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Exome sequencing of tumors from the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development
Egle, A; Gassner, FJ; Hopner, JP; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Zaborsky, N
ONCOL RES TREAT. 2018; 41: 31-31.
Abstracts (Zeitschrift)
Deletion of the p53 Target Gene PUMA Prevents Bone Marrow Failure in a Dyskeratosis Congenita Mouse Model
Erlacher, M; Molnar, C; Weiss, JM; Bohler, S; Steinemann, D; Gohring, G; Villunger, A; Labi, V; Niemeyer, C; Egle, A
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera - Final Phase I/II Peginvera Study Results
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Forjan, E; Willenbacher, E; Wolf, D; Kralovics, R; Gisslinger, B; Stampfl-Mattersberger, M; Egle, A; Melchardt, T; Burgstaller, S; Schalling, M; Krauth, MT; Greil, R; Kadlecova, P; Zoerer, M; Empson, V; Grohmann-Izay, B; Klade, C
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer
Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Geisberger, R; Asslaber, D; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 307-307.
Abstracts (Zeitschrift)
The HIV continuum of care in Austria from 2010 to 2016: data and challenges
Leierer, G; van Sighem, A; Rieger, A; Schmied, B; Sarcletti, M; Ollinger, A; Haas, B; Egle, A; Rappold, M; Zangerle, R
J INT AIDS SOC. 2018; 21:
Abstracts (Zeitschrift)
Spatial heterogeneity in diffuse large B-cell lymphoma
Magnes, T; Melchardt, T; Thorner, A; Neureiter, D; Klieser, E; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 243-244.
Abstracts (Zeitschrift)

2017

Beiträge in Fachzeitschriften

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.
Catakovic, K; Gassner, FJ; Ratswohl, C; Zaborsky, N; Rebhandl, S; Schubert, M; Steiner, M; Gutjahr, JC; Pleyer, L; Egle, A; Hartmann, TN; Greil, R; Geisberger, R;
Oncoimmunology. 2017; 7(1):e1371399
Originalarbeiten (Zeitschrift)
Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo.
Egle, A
MEMO-MAG EUR MED ONC. 2017; 10(1): 8-12.
Übersichtsarbeiten
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer, F; Dejaco, M; Grabmer, C; Melchardt, T; Neureiter, D; Mayer, G; Egle, A; Greil, R; Weiss, L;
Wien Klin Wochenschr. 2017; 129(3-4):-144
Fallberichte
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka, L; Drucker, C; Skrabs, C; Thomas, W; Melchardt, T; Struve, S; Bergmann, M; Staber, PB; Porpaczy, E; Einberger, C; Heinz, M; Hauswirth, A; Raderer, M; Pabinger, I; Thalhammer, R; Egle, A; Wendtner, CM; Follows, G; Hoermann, G; Quehenberger, P; Jilma, B; Jaeger, U;
Leukemia. 2017; 31(5): 1117-1122.
Originalarbeiten (Zeitschrift)
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Kiesewetter, B; Willenbacher, E; Willenbacher, W; Egle, A; Neumeister, P; Voskova, D; Mayerhoefer, ME; Simonitsch-Klupp, I; Melchardt, T; Greil, R; Raderer, M;
Blood. 2017; 129(3):-385
Originalarbeiten (Zeitschrift)
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
Leisch, M; Weiss, L; Lindlbauer, N; Jungbauer, C; Egle, A; Rohde, E; Greil, R; Grabmer, C; Pleyer, L;
Leuk Res. 2017; 59:12-19
Originalarbeiten (Zeitschrift)
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.
Magnes, T; Egle, A; Greil, R; Melchardt, T;
MEMO-MAG EUR MED ONC. 2017; 10(4): 220-223.
Übersichtsarbeiten
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes, T; Melchardt, T; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Gampenrieder, S; Moser, G; Gaggl, A; Greil, R; Egle, A;
PLoS One. 2017; 12(7):e0180995
Originalarbeiten (Zeitschrift)
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
Weiss, L; Melchardt, T; Egle, A; Hopfinger, G; Hackl, H; Greil, R; Barth, J; Rummel, M;
Ann Hematol. 2017; 96(7): 1155-1162.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B-AN UPDATE FROM THE PEGINVERA STUDY
Buxhofer-Ausch, V; Grohmann-Izay, B; Thaler, J; Schloegl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Greil, R; Zoerer, M; Kadlecova, P; Klade, C; Gisslinger, H
HAEMATOLOGICA. 2017; 102: 284-284.
Abstracts (Zeitschrift)
Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Steiner, M; Fuentes, CM; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R
ANN ONCOL. 2017; 28:
Abstracts (Zeitschrift)
Casein Kinase 1 delta/epsilon inhibition blocks CLL chemotaxis and delays leukemia onset in the E mu-TCL1 mouse model of chronic lymphocytic leukemia
Janovska, P; Verner, J; Kohoutek, J; Bryjoval, L; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Gregorova, M; Egle, A; Pavlova, S; Poppova, L; Pospisilova, S; Bryja, V
LEUKEMIA LYMPHOMA. 2017; 58: 210-211.
Abstracts (Zeitschrift)

2016

Beiträge in Fachzeitschriften

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil, R; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Fridrik, M; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Pleyer, L; Melchardt, T; Klingler, A; Mayer, J; Egle, A;
Lancet Haematol. 2016; 3(7):e317-e329
Originalarbeiten (Zeitschrift)
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
Hanna, BS; McClanahan, F; Yazdanparast, H; Zaborsky, N; Kalter, V; Rößner, PM; Benner, A; Dürr, C; Egle, A; Gribben, JG; Lichter, P; Seiffert, M;
Leukemia. 2016; 30(3): 570-579.
Originalarbeiten (Zeitschrift)
The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.
Hofbauer, SW; Krenn, PW; Piñόn Hofbauer, J; Pucher, S; Asslaber, D; Egle, A; Hartmann, TN; Greil, R;
Br J Haematol. 2016; 172(5):815-819
Letter
CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.
Kocher, T; Asslaber, D; Zaborsky, N; Flenady, S; Denk, U; Reinthaler, P; Ablinger, M; Geisberger, R; Bauer, JW; Seiffert, M; Hartmann, TN; Greil, R; Egle, A; Piñón Hofbauer, J;
Leukemia. 2016; 30(6):1409-1413
Letter
Bcl-2 proteins in development, health, and disease of the hematopoietic system.
Kollek, M; Müller, A; Egle, A; Erlacher, M;
FEBS J. 2016; 283(15): 2779-2810.
Übersichtsarbeiten
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.
Krenn, PW; Hofbauer, SW; Pucher, S; Hutterer, E; Hinterseer, E; Denk, U; Asslaber, D; Ganghammer, S; Sternberg, C; Neureiter, D; Aberger, F; Wickström, SA; Egle, A; Greil, R; Hartmann, TN;
Cancer Res. 2016; 76(8):218-296
Originalarbeiten (Zeitschrift)
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.
Magnes, T; Melchardt, T; Weiss, L; Hufnagl, C; Greil, R; Egle, A;
J Clin Oncol. 2016; 34(20):2433-2434
Letter
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
Melchardt, T; Hufnagl, C; Weinstock, DM; Kopp, N; Neureiter, D; Tränkenschuh, W; Hackl, H; Weiss, L; Rinnerthaler, G; Hartmann, TN; Greil, R; Weigert, O; Egle, A;
Oncotarget. 2016; 7(32):51494-51502
Originalarbeiten (Zeitschrift)
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka, KT; Melchardt, T; Posch, F; Schlick, K; Deutsch, A; Beham-Schmid, C; Weiss, L; Gary, T; Neureiter, D; Klieser, E; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Br J Cancer. 2016; 115(10):1264-1272
Originalarbeiten (Zeitschrift)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron, AC; Fazi, C; Agathangelidis, A; Villamor, N; Letestu, R; Nomdedeu, J; Palacio, C; Stehlikova, O; Kreuzer, KA; Liptrot, S; O"Brien, D; de Tute, RM; Marinov, I; Hauwel, M; Spacek, M; Dobber, J; Kater, AP; Gambell, P; Soosapilla, A; Lozanski, G; Brachtl, G; Lin, K; Boysen, J; Hanson, C; Jorgensen, JL; Stetler-Stevenson, M; Yuan, C; Broome, HE; Rassenti, L; Craig, F; Delgado, J; Moreno, C; Bosch, F; Egle, A; Doubek, M; Pospisilova, S; Mulligan, S; Westerman, D; Sanders, CM; Emerson, R; Robins, HS; Kirsch, I; Shanafelt, T; Pettitt, A; Kipps, TJ; Wierda, WG; Cymbalista, F; Hallek, M; Hillmen, P; Montserrat, E; Ghia, P;
Leukemia. 2016; 30(4):929-936
Originalarbeiten (Zeitschrift)
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.
Troppan, KT; Melchardt, T; Wenzl, K; Schlick, K; Deutsch, A; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Tränkenschuh, W; Greil, R; Neumeister, P; Egle, A; Pichler, M;
J Clin Pathol. 2016; 69(4):326-330
Originalarbeiten (Zeitschrift)
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.
Zaborsky, N; Gassner, FJ; Asslaber, D; Reinthaler, P; Denk, U; Flenady, S; Hofbauer, JP; Danner, B; Rebhandl, S; Harrer, A; Geisberger, R; Greil, R; Egle, A;
Oncotarget. 2016; 7(31):4945-49469
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

CXCL12 ANTAGONISM BY THE L-RNA APTAMER OLAPTESED PEGOL IS EFFECTIVE AS A MOBILIZING AND THERAPEUTIC AGENT IN A MURINE CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
Hinterseer, E; Hutterer, E; Krenn, PW; Reinthaler, P; Hopner, J; Hopfinger, M; Eulberg, D; Maasch, C; Kruschinski, A; Vater, A; Egle, A; Greil, R; Hartmann, TN
HAEMATOLOGICA. 2016; 101: 45-46.
Abstracts (Zeitschrift)
An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer
Winder, T; Posch, F; Asamer, E; Stotz, M; Siebenhuner, A; Schlick, K; Magnes, T; Samaras, P; Szkandera, J; Clavien, PA; Neureiter, D; Greil, R; Pestalozzi, BC; Stoeger, H; Gerger, A; Egle, A; Pichler, M
ANN ONCOL. 2016; 27:
Abstracts (Zeitschrift)

2015

Beiträge in Fachzeitschriften

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer, S; Hutterer, E; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, PW; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Kruschinski, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, TN;
Oncotarget. 2015; 6(14):12048-12060
Originalarbeiten (Zeitschrift)
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
Gassner, FJ; Zaborsky, N; Catakovic, K; Rebhandl, S; Huemer, M; Egle, A; Hartmann, TN; Greil, R; Geisberger, R;
Br J Haematol. 2015; 170(4):515-522
Originalarbeiten (Zeitschrift)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger, H; Zagrijtschuk, O; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Them, NC; Kadlecova, P; Klade, C; Greil, R;
Blood. 2015; 126(15):1762-1769
Originalarbeiten (Zeitschrift)
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.
Huemer, F; Melchardt, T; Tränkenschuh, W; Neureiter, D; Moser, G; Magnes, T; Weiss, L; Schlattau, A; Hufnagl, C; Ricken, G; Höftberger, R; Greil, R; Egle, A;
BMC Cancer. 2015; 15:996
Fallberichte
Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study
Leierer, G; Grabmeier-Pfistershammer, K; Steuer, A; Geit, M; Sarcletti, M; Haas, B; Kanatschnig, M; Rappold, M; Zangerle, R; Ledergerber, B; Taylor, N
PLOS ONE. 2015; 10(11):
Originalarbeiten (Zeitschrift)
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt, T; Hufnagl, C; Magnes, T; Weiss, L; Hutarew, G; Neureiter, D; Schlattau, A; Moser, G; Gaggl, A; Tränkenschuh, W; Greil, R; Egle, A;
BMC Cancer. 2015; 15:725
Originalarbeiten (Zeitschrift)
A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Hopfinger, G; Magnes, T; Deutsch, A; Neumeister, P; Hackl, H; Greil, R; Pichler, M; Egle, A;
Br J Haematol. 2015; 168(2):239-245
Originalarbeiten (Zeitschrift)
Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Schlick, K; Huemer, F; Deutsch, A; Neumeister, P; Greil, R; Pichler, M; Egle, A;
J Natl Compr Canc Netw. 2015; 13(12):1501-1508
Originalarbeiten (Zeitschrift)
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Auberger, J; Steinkirchner, S; Pleyer, L; Greil, R; Egle, A;
Leuk Lymphoma. 2015; 56(2):353-360
Originalarbeiten (Zeitschrift)
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.
Sochalska, M; Tuzlak, S; Egle, A; Villunger, A;
FEBS J. 2015; 282(5): 834-849.
Originalarbeiten (Zeitschrift)
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them, NC; Bagienski, K; Berg, T; Gisslinger, B; Schalling, M; Chen, D; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zagrijtschuk, O; Klade, C; Greil, R; Gisslinger, H; Kralovics, R;
Am J Hematol. 2015; 90(4):288-294
Originalarbeiten (Zeitschrift)
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan, KT; Melchardt, T; Deutsch, A; Schlick, K; Stojakovic, T; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Eur J Haematol. 2015; 95(6):538-544
Originalarbeiten (Zeitschrift)
B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.
Zaborsky, N; Holler, C; Geisberger, R; Asslaber, D; Gassner, FJ; Egger, V; Piñón-Hofbauer, J; Kocher, T; Hartmann, TN; Greil, R; Egle, A;
Haematologica. 2015; 100(8):e307-e310
Letter

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
Buxhofer-Ausch, V; Gisslinger, H; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Them, NCC; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Mabtenance trial
Egle, A; Doubek, M; Stehlikova, O; Pleyer, L; Altenhofer, P; Melchardt, T; Smolej, L; Mihaylov, GG; Mikuskova, E; Mayer, J; Greil, R
LEUKEMIA LYMPHOMA. 2015; 56: 123-124.
Abstracts (Zeitschrift)
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Schalling, M; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Krauth, MT; Them, NCC; Kralovics, R; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
Combination of age, ABC-type and intratumoral T-regulator cells are a negative prognostic factors for primary extranodal diffuse large B-cell lymphoma
Tränkenschuh, W; Kemmerling, R; Alinger, B; Melchardt, T; Egle, A; Kiesslich, T; Neureiter, D
PATHOLOGE . 2015; 36: 110-110.
Abstracts (Zeitschrift)

2014

Beiträge in Fachzeitschriften

Old and new news in CLL: "It"s the pathway, stupid!".
Egle, A;
Blood. 2014; 124(7):989-990
Letter
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Melchardt, T; Egle, A; Rebhandl, S; Catakovic, K; Hartmann, TN; Greil, R; Geisberger, R;
Haematologica. 2014; 99(5):67-69
Letter
Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.
Grössinger, EM; Weiss, L; Zierler, S; Rebhandl, S; Krenn, PW; Hinterseer, E; Schmölzer, J; Asslaber, D; Hainzl, S; Neureiter, D; Egle, A; Piñón-Hofbauer, J; Hartmann, TN; Greil, R; Kerschbaum, HH;
Leukemia. 2014; 28(4):954-958
Letter
Kasabach-Merritt phenomenon in hepatic angiosarcoma.
Habringer, S; Boekstegers, A; Weiss, L; Hopfinger, G; Meissnitzer, T; Melchardt, T; Egle, A; Greil, R;
Br J Haematol. 2014; 167(5):716-718
Letter
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger, G; Nösslinger, T; Lang, A; Linkesch, W; Melchardt, T; Weiss, L; Egle, A; Greil, R;
Ann Hematol. 2014; 93(3):459-462
Originalarbeiten (Zeitschrift)
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater, AP; Tonino, SH; Egle, A; Ramsay, AG;
Blood. 2014; 124(14):2184-2189
Übersichtsarbeiten
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Melchardt, T; Magnes, T; Weiss, L; Grundbichler, M; Strasser, M; Hufnagl, C; Moik, M; Greil, R; Egle, A;
BMC COMPLEM ALTERN M. 2014; 14: 115
Fallberichte
Pleural decortication of a marginal zone lymphoma.
Melchardt, T; Weiss, L; Namberger, K; Pretsch, I; Hutter, J; Rettenbacher, L; Neureiter, D; Troch, M; Greil, R; Egle, A;
Ann Hematol. 2014; 93(7):1253-1254
Letter
Human immunodeficiency virus type 2 infections in Austria.
Taylor, N; Kern, JM; Prammer, W; Lang, A; Haas, B; Gisinger, M; Zangerle, R; Egle, A; Greil, R; Oberkofler, H; Eberle, J;
Wien Klin Wochenschr. 2014; 126(7-8):212-216
Originalarbeiten (Zeitschrift)
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Troppan, KT; Schlick, K; Deutsch, A; Melchardt, T; Egle, A; Stojakovic, T; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Pichler, M;
Br J Cancer. 2014; 111(1):55-60
Originalarbeiten (Zeitschrift)
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
Weiss, L; Melchardt, T; Habringer, S; Boekstegers, A; Hufnagl, C; Neureiter, D; Hopfinger, G; Greil, R; Egle, A;
Ann Oncol. 2014; 25(1):171-176
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

The integrin VLA-4 shows impaired CXCL12-induced inside-out activation in trisomy12 harboring chronic lymphocytic leukemia (CLL) cells
Ganghammer, S; Hutterer, E; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, PW; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, TN
ONCOL RES TREAT. 2014; 37: 222-222.
Abstracts (Zeitschrift)
CLL INDUCES SEVERE SKEWING IN THE MYELOID COMPARTMENT IN PATIENTS AND IN THE TCL1 MOUSE MODEL
Hanna, B; McClanahan, F; Zaborsky, N; Durr, C; Gschwend, V; Stilgenbauer, S; Egle, A; Gribben, J; Lichter, P; Seiffert, M
HAEMATOLOGICA. 2014; 99: 228-229.
Abstracts (Zeitschrift)
Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model
Hanna, B; McClanahan, F; Zaborsky, N; Durr, C; Kalter, V; Egle, A; Gribben, JG; Lichter, P; Seiffert, M
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
The Spiegelmer (R) NOX-A12 Mobilizes CLL Cells from Lymphoid Organs and Prevents Their Recirculation
Hinterseer, E; Girbl, T; Hutterer, E; Berghammer, P; Ganghammer, S; Sifft, EA; Pinon-Hofbauer, J; Egle, A; Kruschinski, A; Greil, R; Hartmann, TN
SCAND J IMMUNOL. 2014; 79(6): 468-469.
Abstracts (Zeitschrift)
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner
Hutterer, E; Ganghammer, S; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, P; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, T
SCAND J IMMUNOL. 2014; 79(6): 468-468.
Abstracts (Zeitschrift)
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner
Hutterer, E; Ganghammer, S; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, P; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, T
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner. 2014; 79(6): 424-478.-Scandinavian Society for Immunology 42nd Annual Meeting; 11.-14.06.2014; Reykjavik.
Abstracts (Zeitschrift)
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study
Rawstron, A; Fazi, C; Villamor, N; Delgado, J; Letestu, R; Cymbalista, F; Palacio, C; Bosch, F; De Tute, RM; Liptrot, S; OxxxBrien, D; Spacek, M; Dobber, J; Kater, AP; Gambell, PC; Westerman, DA; Soosapilla, A; Mulligan, SP; Lozanski, G; Lin, K; Pettitt, AR; Brachtl, G; Egle, A; Williamson, DW; Sanders, CM; Robins, H; Boysen, J; Shanafelt, TD; Hanson, CA; Jorgensen, JL; Wierda, WG; Yuan, C; Stetler-Stevenson, M; Rassenti, L; Broome, HE; Kipps, TJ; Hauwel, M; Marinov, I; Craig, FE; Josep, N; Moreno, C; Stehlikova, O; Doubek, M; Pospisilova, S; Kreuzer, KA; Hallek, M; Hillmen, P; Montserrat, E; Ghia, P
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)

2013

Beiträge in Fachzeitschriften

Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?
Asslaber, D; Grössinger, EM; Girbl, T; Hofbauer, SW; Egle, A; Weiss, L; Greil, R; Hartmann, TN;
Br J Haematol. 2013; 160(5):711-714
Letter
Bid-ding for mercy: twisted killer in action.
Egle, A; Asslaber, D; Villunger, A; Pinon-Hofbauer, J;
Cell Death Differ. 2013; 20(7):847-849
Editorials
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.
Lutzny, G; Kocher, T; Schmidt-Supprian, M; Rudelius, M; Klein-Hitpass, L; Finch, AJ; Dürig, J; Wagner, M; Haferlach, C; Kohlmann, A; Schnittger, S; Seifert, M; Wanninger, S; Zaborsky, N; Oostendorp, R; Ruland, J; Leitges, M; Kuhnt, T; Schäfer, Y; Lampl, B; Peschel, C; Egle, A; Ringshausen, I;
Cancer Cell. 2013; 23(1):77-92
Originalarbeiten (Zeitschrift)
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?].
Melchardt, T; Weiss, L; Egle, A;
Dtsch Med Wochenschr. 2013; 138(41): 2093-2095.
Fallberichte
What’s new in Hodgkin’s lymphoma: ASH 2012 and more
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 193-196.
Übersichtsarbeiten
Viral infections and their management in patients with chronic lymphocytic leukemia.
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Leuk Lymphoma. 2013; 54(8):1602-1613
Übersichtsarbeiten
Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome.
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Auberger, J; Hopfinger, G; Greil, R; Egle, A;
Oncol Lett. 2013; 6(6):1756-1758
Originalarbeiten (Zeitschrift)
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Sliwa, T; Egle, A; Linkesch, W; Voskova, D; Angermann, H; Greil, R;
J Hematol Oncol. 2013; 6:32
Editorials
Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
Taylor, N; Grabmeier-Pfistershammer, K; Egle, A; Greil, R; Rieger, A; Ledergerber, B; Oberkofler, H;
PLoS One. 2013; 8(8):e74024
Originalarbeiten (Zeitschrift)
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Taylor, N; Melchardt, T; Grundbichler, M; Strasser, M; Egle, A; Greil, R;
Ann Hematol. 2013; 92(7):1001-1002
Letter
p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
Valente, LJ; Gray, DH; Michalak, EM; Pinon-Hofbauer, J; Egle, A; Scott, CL; Janic, A; Strasser, A;
Cell Rep. 2013; 3(5):1339-1345
Originalarbeiten (Zeitschrift)

Originalbeiträge in Sammelwerk (Buchbeitrag)

Diagnostik und Therapie von diffus großzelligen Lymphomen (DLBCL)
Egle, A; Melchardt, T; Weiss, L;
In: Hopfinger, G; Greil, R (Hrsg.) editors(s). Aktuelle Diagnostik und Therapieoptionen bei aggressiven Lymphomen.. Bremen, London, Boston: UniMed Verlag; p. 26-35. (ISBN: 978-3-8374-1407-3)

Beiträge in Sonstigen Zeitschriften

Therapy with JAK 1/2 inhibitors for myelofibrosis
Romeder, F; Greil, R; Egle, A
memo - Magazine of European Medical Oncology, 2013/2. 2013.

2012

Beiträge in Fachzeitschriften

Lysine residue at position 22 of the AID protein regulates its class switch activity.
Geisberger, R; Huemer, M; Gassner, FJ; Zaborsky, N; Egle, A; Greil, R;
PLoS One. 2012; 7(2):e30667
Originalarbeiten (Zeitschrift)
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel, O; Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Kocher, T; Denk, U; Hofbauer, JP; Egle, A; Scheideler, M; Schlederer, M; Steurer, M; Kenner, L; Greil, R;
Leukemia. 2012; 26(12):2508-2516
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia
Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Egle, A; Hartmann, TN; Greil, R; Geisberger, R
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
Gisslinger, H; Kralovics, R; Gisslinger, B; Lechner, D; Buxhofer-Ausch, V; Strecker, K; Gastl, G; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Schloegl, E; Tarmann, FJ; Zoerer, M; Klade, C; Zahriychuk, O; Thaler, J
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
Protein Kinase C-beta Dependent Activation of NF-kappa B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in Vivo
Lutzny, G; Kocher, T; Rudelius, M; Schmidt-Supprian, M; Klein-Hitpass, L; Durig, J; Oostendorp, RAJ; Peschel, C; Egle, A; Ringshausen, I
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
Feasibility of anthracycline based treatment in unselected elderly DLBCL patients
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Hopfinger, G; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 86-87.
Abstracts (Zeitschrift)
Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Greil, R; Egle, A
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 149-149.
Abstracts (Zeitschrift)
Upgraded Cobas TaqMan version 2: hidden consequences at cohort level
Taylor, N; Grabmeier-Pfistershammer, K; Oberkofler, H; Egle, A; Rieger, A; Ledergerber, B
J INT AIDS SOC. 2012; 15: 109-109.
Abstracts (Zeitschrift)

2011

Beiträge in Fachzeitschriften

Treatment of invasive aspergillosis in cancer patients.
Auberger, J; Russ, G; Greil, R; Egle, A;
memo - Magazine of European Medical Oncology. 2011; 4 (4): 266-272.
Übersichtsarbeiten
Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.
Brachtl, G; Sahakyan, K; Denk, U; Girbl, T; Alinger, B; Hofbauer, SW; Neureiter, D; Hofbauer, JP; Egle, A; Greil, R; Hartmann, TN;
PLoS One. 2011; 6(8):e23758
Originalarbeiten (Zeitschrift)
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Gassner, FJ; Weiss, L; Geisberger, R; Hofbauer, JP; Egle, A; Hartmann, TN; Greil, R; Tinhofer, I;
Cancer Immunol Immunother. 2011; 60(1):7-85
Originalarbeiten (Zeitschrift)
Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer, JP; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R; Egle, A;
Leukemia. 2011; 25(9): 1452-1458.
Originalarbeiten (Zeitschrift)
Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria.
Poeppl, W; Hell, M; Herkner, H; Stoiser, B; Fritsche, G; Schurz-Bamieh, N; Poeppl, G; Gattringer, R; Jones, N; Maass, M; Egle, A; Burgmann, H;
Infection. 2011; 39(4):341-352
Originalarbeiten (Zeitschrift)
Raltegravir in pregnancy: a case series presentation.
Taylor, N; Touzeau, V; Geit, M; Gisinger, M; Egle, A; Greil, R; Rieger, A; Zangerle, R;
Int J STD AIDS. 2011; 22(6): 358-360.
Fallberichte
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
Weiss, L; Melchardt, T; Egle, A; Grabmer, C; Greil, R; Tinhofer, I;
Cancer. 2011; 117(10):2163-2169
Originalarbeiten (Zeitschrift)
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Weiss, L; Melchardt, T; Neureiter, D; Kemmerling, R; Moshir, S; Pleyer, L; Greil, R; Egle, A;
J CLIN ONCOL. 2011; 29(24): e696-e698.
Fallberichte

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

CLL CELLS INDUCE CLONAL T CELL SKEWING AND SUBSETSHIFTING IN THE MURINE TCL1 TRANSGENIC CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
Egle, A; Pinon-Hofbauer, J; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R
ANN ONCOL. 2011; 22: 144-144.
Abstracts (Zeitschrift)
A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results
Egle, A; Steurer, M; Gassner, F; Geisberger, R; Melchardt, T; Weiss, L; Fridrik, MA; Thaler, J; Lang, A; Greil, R
BLOOD. 2011; 118(21): 135-136.
Abstracts (Zeitschrift)
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
Gisslinger, H; Kralovics, R; Schoder, R; Gisslinger, B; Buxhofer-Ausch, V; Strecker, K; Wolf, D; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Tarmann, FJ; Wachter, C; Zahriycick, O; Thaler, J
BLOOD. 2011; 118(21): 762-762.
Abstracts (Zeitschrift)
Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia
Holler, C; Zaborsky, N; Hofbauer, JP; Kocher, T; Trapin, D; Asslaber, D; Greil, R; Egle, A
BLOOD. 2011; 118(21): 365-365.
Abstracts (Zeitschrift)
Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Egle, A; Sliwa, T; Linkesch, W; Fridrik, MA; Greil, R
BLOOD. 2011; 118(21): 747-747.
Abstracts (Zeitschrift)
Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia
Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Denk, U; Pinon-Hofbauer, J; Egle, A; Kocher, T; Steurer, M; Greil, R; Merkel, O
ONKOLOGIE. 2011; 34: 141-141.
Abstracts (Zeitschrift)

2010

Beiträge in Fachzeitschriften

MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.
Asslaber, D; Pinon Hofbauer, J; Greil, R; Egle, A
Journal of nucleic acids investigation. 2010; Dec 1, 1(1): 76-80.
Originalarbeiten (Zeitschrift)
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber, D; Piñón, JD; Seyfried, I; Desch, P; Stöcher, M; Tinhofer, I; Egle, A; Merkel, O; Greil, R;
Blood. 2010; 115(21):4191-4197
Originalarbeiten (Zeitschrift)
Riding the 2-edged sword.
Egle, A;
Blood. 2010; 115(22): 4325-4326.
Letter
Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.
Labi, V; Erlacher, M; Krumschnabel, G; Manzl, C; Tzankov, A; Pinon, J; Egle, A; Villunger, A;
Genes Dev. 2010; 24(15):1602-1607
Originalarbeiten (Zeitschrift)
An uncommon cause of anaemia: Sheehan"s syndrome.
Melchardt, T; Namberger, K; Weiss, L; Egle, A; Faber, V; Greil, R;
WIEN KLIN WOCHENSCHR. 2010; 122(23-24): 717-719.
Fallberichte
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.
Merkel, O; Asslaber, D; Piñón, JD; Egle, A; Greil, R;
Cell Cycle. 2010; 9(14):2764-2768
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study
Egle, A; Weiss, L; Melchardt, T; Gunsilius, E; Petzer, AL; Fridrik, M; Lang, A; Krieger, O; Thaler, J; Greil, R
BLOOD. 2010; 116(21): 593-594.
Abstracts (Zeitschrift)
Deletion of Puma and p21(Waf1) In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence
Hofbauer, JP; Holler, C; Denk, U; Asslaber, D; Fastner, G; Labi, V; Villunger, A; Greil, R; Egle, A
BLOOD. 2010; 116(21): 45-46.
Abstracts (Zeitschrift)
Enzastaurin kills human CLL cells regardless of clinical risk profile, but fails to prolong life in a murine CLL model
Kocher, T; Pinon, HJ; Holler, C; Denk, U; Greil, R; Egle, A
ONKOLOGIE. 2010; 33: 40-40.
Abstracts (Zeitschrift)
Tumour suppression by BH3-only proteins, proapoptotic members of the Bcl-2 family
Villunger, A; Labi, V; Frenzel, A; Egle, A; Pinon, J
EJC SUPPL. 2010; 8(5): 1-1.
Abstracts (Zeitschrift)

2009

Beiträge in Fachzeitschriften

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann, TN; Pleyer, L; Desch, P; Egle, A; Greil, R;
Discov Med. 2009; 8(42): 157-164.
Übersichtsarbeiten
PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler, C; Piñón, JD; Denk, U; Heyder, C; Hofbauer, S; Greil, R; Egle, A;
Blood. 2009; 113(12):2791-2794
Originalarbeiten (Zeitschrift)
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer, L; Egle, A; Hartmann, TN; Greil, R;
NAT REV CLIN ONCOL. 2009; 6(7): 405-418.
Übersichtsarbeiten
Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.
Taylor, N; Schmid, I; Egle, A; Greil, R; Patsch, W; Oberkofler, H;
Antivir Ther. 2009; 14(8): 118-193.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY
Egle, A; Melchardt, T; Pleyer, L; Tinhofer, I; Lang, A; Keil, F; Thaler, J; Gunsilius, E; Fridrik, M; Greil, R
HAEMATOL-HEMATOL J. 2009; 94: 140-140.
Abstracts (Zeitschrift)
The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis
Egle, A; Steurer, M; Melchardt, T; Stoll, M; Greil, R
BLOOD. 2009; 114(22): 1341-1342.
Abstracts (Zeitschrift)
The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia
Weiss, L; Melchardt, T; Grabmer, C; Egle, A; Tinhofer, I; Greil, R
BLOOD. 2009; 114(22): 510-510.
Abstracts (Zeitschrift)

2008

Beiträge in Fachzeitschriften

Bim and Bmf in tissue homeostasis and malignant disease.
Piñon, JD; Labi, V; Egle, A; Villunger, A;
Oncogene. 2008; 27 Suppl 1:S41-S52
Übersichtsarbeiten

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcll Transgenic Chronic Lymphocytic Leukemia Model
Egle, A; Pinon, JD; Heyder, C; Holler, C; Denk, U; Tinhofer, I; Greil, R
BLOOD. 2008; 112(11): 1078-1078.
Abstracts (Zeitschrift)
Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.
Egle, A; Weiss, L; Gassner, F; Russ, G; Pleyer, L; Gunsilius, E; Tinhofer, I; Thaler, J; Petzer, AL; Greil, R
BLOOD. 2008; 112(11): 1089-1089.
Abstracts (Zeitschrift)

2007

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study
Egle, A; Weiss, L; Russ, G; Thoedtmann, R; Pleyer, L; Gastl, G; Thaler, J; Petzer, A; Tinhofer, I; Greil, R
BLOOD. 2007; 110(11): 609A-609A.
Abstracts (Zeitschrift)

Originalbeiträge in Sammelwerk (Buchbeitrag)

Follikuläres Lymphom.
Egle, A;
In: Greil, R (Ed.) editors(s). Lymphoproliferative Erkrankungen.. p. 93-107.

2006

Beiträge in Fachzeitschriften

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.
Tinhofer, I; Rubenzer, G; Holler, C; Hofstaetter, E; Stoecher, M; Egle, A; Steurer, M; Greil, R;
Blood. 2006; 108(9):2950-2956
Originalarbeiten (Zeitschrift)
The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
Tinhofer, I; Steurer, M; Leitinger, G; Rumpold, H; Egle, A; Erdel, M; Greil, R;
Haematologica. 2006; 91(9): 1291-1293.
Letter

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Planned first safety and efficacy analysis of oral fludarabine combined with subcutaneous alemtuzumab in 2(nd) line therapy of B-chronic lymphocytic leukaemia (B-CLL): The FLUSALEM study.
Egle, A; Tinhofer, I; Russ, G; Rass, C; Greil, R
BLOOD. 2006; 108(11): 336B-336B.
Abstracts (Zeitschrift)

2005

Beiträge in Fachzeitschriften

Subversion of the Bcl-2 life/death switch in cancer development and therapy.
Adams, JM; Huang, DC; Strasser, A; Willis, S; Chen, L; Wei, A; van Delft, M; Fletcher, JI; Puthalakath, H; Kuroda, J; Michalak, EM; Kelly, PN; Bouillet, P; Villunger, A; O"Reilly, L; Bath, ML; Smith, DP; Egle, A; Harris, AW; Hinds, M; Colman, P; Cory, S;
Cold Spring Harb Symp Quant Biol. 2005; 70: 469-477.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Expression levels of CD38 in tumor cells and T-cells are of prognostic value in B-CLL
Tinhofer, I; Rubenzer, G; Egle, A; Greil, R
BLOOD. 2005; 106(11): 347A-347A.
Abstracts (Zeitschrift)

2004

Beiträge in Fachzeitschriften

VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.
Egle, A; Harris, AW; Bath, ML; O"Reilly, L; Cory, S;
Blood. 2004; 103(6):2276-2283
Originalarbeiten (Zeitschrift)
Bim is a suppressor of Myc-induced mouse B cell leukemia.
Egle, A; Harris, AW; Bouillet, P; Cory, S;
P NATL ACAD SCI USA. 2004; 101(16): 6164-6169.
Originalarbeiten (Zeitschrift)
Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation.
Scott, CL; Schuler, M; Marsden, VS; Egle, A; Pellegrini, M; Nesic, D; Gerondakis, S; Nutt, SL; Green, DR; Strasser, A;
J CELL BIOL. 2004; 164(1): 8-96.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Making life and death decisions for cells
Cory, S; Egle, A; Bouillet, P; Puthalakath, H; Marsden, V; Hinds, M; Harris, A; Huang, D; Adams, J; Strasser, A; Day, C
FASEB J. 2004; 18(8): C225-C225.
Abstracts (Zeitschrift)

2003

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Bim acts as a haploinsufficient and anti-leukemic tumor suppressor in Myc-induced lymphoma.
Egle, A; Bouillet, P; Harris, AW; Cory, S
BLOOD. 2003; 102(11): 135A-135A.
Abstracts (Zeitschrift)
VavP-Bc/2 transgenic mice develop clonal follicular lyraphoma preceded by germinal center hyperplasia.
Egle, A; Harris, AL; Bath, ML; OxxxReilly, L; Cory, S
BLOOD. 2003; 102(11): 67A-67A.
Abstracts (Zeitschrift)

2001

Beiträge in Fachzeitschriften

TNF cytokine family: more BAFF-ling complexities.
Laâbi, Y; Egle, A; Strasser, A;
Curr Biol. 2001; 11(24): R1013-R1016.
Übersichtsarbeiten

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Stepping up treatment with Rituxan (R) (rituximab, Mabthera (R)) for CLL patients with advanced stage of disease relapsing after or refractory to conventional chemotherapy.
Greil, R; Steurer, M; Egle, A; Stauder, R; Anether, G; Ulmer, L; Tinhofer, I; Gastl, G
BLOOD. 2001; 98(11): 289B-290B.
Abstracts (Zeitschrift)

2000

Beiträge in Fachzeitschriften

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.
Marschitz, I; Tinhofer, I; Hittmair, A; Egle, A; Kos, M; Greil, R;
Am J Clin Pathol. 2000; 113(2): 21-29.
Originalarbeiten (Zeitschrift)
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
Tinhofer, I; Marschitz, I; Henn, T; Egle, A; Greil, R;
Blood. 2000; 95(2): 610-618.
Originalarbeiten (Zeitschrift)

1998

Beiträge in Fachzeitschriften

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil, R; Egle, A; Villunger, A;
Leuk Lymphoma. 1998; 31(5-6): 477-490.
Übersichtsarbeiten
Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R;
Blood. 1998; 91(11): 4273-4281.
Originalarbeiten (Zeitschrift)
Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Villunger, A; Egle, A; Kos, M; Egle, D; Tinhofer, I; Henn, T; Uberall, F; Maly, K; Greil, R;
Br J Haematol. 1998; 102(4): 1069-1080.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Inversion of CD4(+)/CD8(+) ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4(+) and CD8(+) T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells.
Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R
BLOOD. 1998; 92(10): 271B-271B.
Abstracts (Zeitschrift)

1997

Beiträge in Fachzeitschriften

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle, A; Villunger, A; Marschitz, I; Kos, M; Hittmair, A; Lukas, P; Grünewald, K; Greil, R;
BRIT J HAEMATOL. 1997; 97(2): 41-28.
Originalarbeiten (Zeitschrift)
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.
Geley, S; Hartmann, BL; Kapelari, K; Egle, A; Villunger, A; Heidacher, D; Greil, R; Auer, B; Kofler, R;
FEBS Lett. 1997; 402(1): 36-40.
Originalarbeiten (Zeitschrift)
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger, A; Egle, A; Kos, M; Hartmann, BL; Geley, S; Kofler, R; Greil, R;
Cancer Res. 1997; 57(16): 3331-3334.
Originalarbeiten (Zeitschrift)
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger, A; Egle, A; Marschitz, I; Kos, M; Böck, G; Ludwig, H; Geley, S; Kofler, R; Greil, R;
BLOOD. 1997; 90(1): 12-20.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Fas (Apo-1/CD95) - Ligand expression on neoplastic plasma cells and its role for the expansion of the neoplastic clone.
Greil, R; Villunger, A; Egle, A; Marschitz, L; Kos, M; Bock, G; Ludwig, H; Geley, S; Kofler, R
BLOOD. 1997; 90(10): 1578-1578.
Abstracts (Zeitschrift)

1996

Beiträge in Fachzeitschriften

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.
Egle, A; Marschitz, I; Posch, B; Herold, M; Greil, R;
Br J Haematol. 1996; 94(1):211-212
Letter
Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.
Egle, A; Villunger, A; Kos, M; Böck, G; Gruber, J; Auer, B; Greil, R;
Eur J Immunol. 1996; 26(12): 3119-3126.
Originalarbeiten (Zeitschrift)
2",2"-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Gruber, J; Geisen, F; Sgonc, R; Egle, A; Villunger, A; Boeck, G; Konwalinka, G; Greil, R;
Stem Cells. 1996; 14(3):351-362
Originalarbeiten (Zeitschrift)
Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
Villunger, A; Egle, A; Kos, M; Hittmair, A; Maly, K; Greil, R;
Int J Cancer. 1996; 65(4):498-505
Originalarbeiten (Zeitschrift)

1991

Beiträge in Fachzeitschriften

B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance.
Hofmann, J; Ueberall, F; Egle, A; Grunicke, H;
Int J Cancer. 1991; 47(6):870-874
Originalarbeiten (Zeitschrift)
Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35.
Uberall, F; Maly, K; Egle, A; Doppler, W; Hofmann, J; Grunicke, HH;
Cancer Res. 1991; 51(21):5821-5825
Originalarbeiten (Zeitschrift)